Question 1

Will my Medicare Advantage revenue go up or down in 2027?

Accepted Answer

The headline is a 2.48% average increase in plan payments, but the number that reaches your practice is different. Plans lose the diagnoses they used to add through unlinked chart reviews (about 1.5% of revenue), V28 continues to pay less for many common conditions, and the big carriers are pricing 2027 bids for margin recovery. In practice that means capitation rates that grow slower than your costs, more quality withholds, and contract language that pushes RADV recoupments down to you. If you are paid fee-for-service, the proposed PFS conversion factor drops 1.19% to 1.68%. Nelangie Cares starts with a revenue exposure review: which of your MA contracts are percent-of-premium or risk-adjusted, how much of your risk score depended on plan chart reviews, and where your quality withholds sit. We then redesign the visit workflow so every diagnosis that is still payable under V28 is assessed, documented, and coded at the face-to-face visit, and we build the quality gap and pending-appointment reports your team works every month. The goal is that your 2027 revenue rests on what happens in your exam room, not on retrospective plan activity that no longer counts.

Question 2

What does the end of unlinked chart review diagnoses actually mean for my practice?

Accepted Answer

Beginning with 2027 payments, a diagnosis only counts if it is linked to a real encounter (yours, a specialist's, or a hospital's). A plan can no longer send a coder through last year's records and add conditions that were never addressed at a visit. If your patient with CKD stage 3 or heart failure was not seen and documented this year, that condition disappears from the risk score, and so does the payment tied to it. For capitated practices that is direct revenue; for fee-for-service practices it shows up as plans leaning harder on you for annual visits, suspect-condition outreach, and documentation quality. We build a prospective recapture workflow: a pre-visit suspect list drawn from your EHR, claims, and pharmacy data; point-of-care prompts inside your templates; and MEAT-standard documentation (Monitor, Evaluate, Assess, Treat) so every chronic condition is supported. We train your medical assistants and providers in a two-day onboarding, then run a coder-to-clinician feedback loop each month. We also set a visit cadence of four to six touches a year for chronic patients so nothing waits until December.

Question 3

I keep hearing about RADV audits. Am I exposed, or is that the plan's problem?

Accepted Answer

It is now both. CMS audits all roughly 550 MA contracts every year, samples up to 200 records per contract, and is clearing payment years 2020 through 2025 on a rolling schedule through 2027. Auditors request the medical record from your office, and an unsupported diagnosis is recouped from the plan. Most 2027 provider contracts include clauses that pass that recoupment, and sometimes penalties, to the practice. Extrapolation across the whole contract is on hold after a 2025 court ruling, but CMS has appealed, and even sample-only audits already reach your charts. Nelangie Cares runs a documentation integrity audit on your risk-adjusted population, scoring each HCC against RADV support standards and flagging the ones a reviewer would reject (unsigned notes, conditions listed without assessment, copy-forward problem lists). We fix the templates that create those gaps, train the team, and set up a record-retrieval process so an audit request is a same-week task instead of a fire drill. We also review the RADV and clawback language in your plan contracts before you sign.

Question 4

Which Star Ratings measures should I focus on now that CMS removed a dozen of them?

Accepted Answer

CMS removed administrative measures (call center, appeals, complaints, disenrollment, several CAHPS items), which means the clinical measures you control now carry more of the plan's rating and of your incentive dollars. The measures that matter for 2027 and 2028: Controlling Blood Pressure, HbA1c control, Kidney Health Evaluation, Eye Exam (kept after pushback), breast and colorectal cancer screening (colorectal is respecified), the three Part D adherence measures (statins, RAS antagonists, diabetes medications), and the new Functional Status Assessment, Polypharmacy, and Opioid-Benzodiazepine measures. Improving or Maintaining Physical and Mental Health, which come from the patient survey, now weigh 3x. Depression Screening and Follow-Up arrives for the 2029 ratings. We convert this list into a monthly working file for your practice: who is uncontrolled, who is due, who has not filled a statin, who is on more than one anticholinergic, and which appointments are pending. We redesign the rooming workflow so blood pressure recheck, PHQ screening, fall risk, and functional status are captured before the provider walks in, and we align your pharmacy outreach with plan adherence calendars. Because the physical and mental health measures are survey-based, we also coach the team on the care experience that drives those responses.

Question 5

The fee schedule is going down again. How do I protect fee-for-service revenue in 2027?

Accepted Answer

Under the proposed rule the conversion factor falls 1.19% for clinicians in an advanced APM and 1.68% for everyone else. G2211, the visit-complexity add-on, becomes a modifier worth 16% of the base E/M, or 32% if you participate in MSSP or LEAD, which is a meaningful reward for ACO participation. New codes cover advance care planning by clinical staff and shared medical appointments. Care management codes (CCM, PCM, TCM, APCM) were exempt from the 2026 efficiency cut and remain the most durable primary care revenue line. Nelangie Cares builds the care management program most practices leave on the table: Chronic Care Management with prefilled, condition-specific care plans (hypertension, diabetes, heart failure, atrial fibrillation, COPD, hyperlipidemia), Transitional Care Management after every discharge, Annual Wellness Visits with integrated social-needs screening, and Advance Care Planning. We handle enrollment scripts, consent, time tracking, and the billing rules (for example, CCM and TCM cannot both be billed in the same month). For multilingual panels we deploy AI-supported language tools so staffing cost does not eat the margin.

Question 6

Should I join an ACO in 2027, and which one?

Accepted Answer

For most independent primary care practices the answer in 2027 is yes. MSSP participants would get the 32% G2211 modifier, are exempt from the larger fee cut, and can now offer patients Part B cost-sharing support from April 2027 under the proposed rule. The trade-off is that one-sided (no downside) risk in the BASIC track is now capped at five years for agreements starting in 2027, and CMS is ending prepaid shared savings after the 2027 cohort. LEAD, the 10-year successor to ACO REACH, closed applications in May 2026, so joining it for 2027 means becoming a participant TIN in an ACO that was accepted; participation is whole-TIN, a TIN cannot be in both MSSP and LEAD, and Professional-option LEAD ACOs pay primary care through capitation rather than fee-for-service. CMS expects future LEAD application windows but has not announced dates. We run an ACO readiness assessment: your attributed lives, cost benchmarks, quality reporting capability, and which track or ACO partner fits. We check your assignment position (which of your codes count as primary care for attribution, including the new 2027 additions), compare the MSSP and LEAD participation terms on offer in your market, and prepare your practice for capitation cash flow if a LEAD ACO is the right fit. Once you are in, we build the eCQM and Medicare CQM reporting workflow and the monthly performance review so shared savings become predictable instead of a surprise at reconciliation.

Question 7

What is changing with prior authorization, and does the WISeR model affect me?

Accepted Answer

For MA, the CY 2027 rule did not add new prior authorization rules, but the CMS-0057 interoperability rule still requires plans to run an electronic prior authorization API by Jan 1, 2027, with 72-hour urgent and 7-day standard decisions and specific denial reasons. WISeR, the AI-assisted prior authorization model in traditional Medicare, is live in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington for services such as skin substitutes, epidural injections, and nerve stimulators, though Congress is trying to defund it. The mandatory Ambulatory Specialty Model that starts in 2027 also nudges cardiology and pain specialists toward electronic prior authorization. We map your current authorization workflow, identify the services and payors that generate denials, and rebuild the intake so requests go out complete the first time. We create a denial log with root-cause categories and review it with you monthly. For practices in WISeR states, we set up a referral pathway that anticipates the documentation the vendor will ask for, so patient care is not delayed.

Question 8

Plans are exiting my market and patients are switching. How do I keep my panel stable?

Accepted Answer

Humana, UnitedHealthcare, Centene, and Aetna are all trimming plans, counties, and benefits for 2027. During the Oct 15 to Dec 7 enrollment period, patients will change plans, some will land in plans where you are out of network, and the ones who switch MA organizations fall under a special risk adjustment exception in 2027. Every switch resets your quality denominators, attribution, and, for capitated practices, revenue. We build a panel management routine: a roster reconciliation each month, outreach to patients whose plan is terminating, and a January-through-March visit push so new and switching patients are seen early, their conditions documented, and their care gaps opened for the year. We also make sure your practice is listed accurately in plan directories, which became a bigger driver of enrollment as plans changed their benefits.

Question 9

ACO REACH ends December 31, 2026. What exactly is the LEAD Model, and where do we stand in its timeline?

Accepted Answer

LEAD (Long-term Enhanced ACO Design) is the 10-year successor to ACO REACH, announced December 18, 2025 and running PY2027 through PY2036. The request for applications opened March 31, 2026, applications closed May 17, 2026, and CMS said it would notify selected ACOs by early summer; on September 21, 2026 CMS published a list of 79 ACOs in the Implementation Period and said it is working with well over 100 ACOs preparing for PY2027 (updated Oct 2026). Three dates matter now: September 11, 2026 was the deadline to remove participant TINs and resolve TIN overlap between MSSP and LEAD rosters (a TIN cannot sit in both) (updated Oct 2026); the optional implementation period runs September 15 to December 31, 2026, when ACOs can begin voluntary alignment but there is no payment or risk (updated Oct 2026); and PY2027 starts January 1, 2027. CMS anticipates additional application windows for later performance years but has not announced dates. PY2026 REACH ACOs used an abbreviated application, which is continuity rather than a formal preference. If you were accepted, Nelangie Cares helps you use the implementation period the way it was intended: participant TIN readiness reviews, alignment forecasting from your claims-based plurality data, and the practice-level workflows that a 10-year fixed benchmark rewards. If you were not selected or did not apply, we build your MSSP transition plan, including the one-time BASIC/ENHANCED track switch CMS proposed for January 2027 applicants and a readiness roadmap for a future LEAD cohort so the next window is a decision, not a scramble.

Question 10

How does LEAD's financial design differ from REACH, and what does it mean for our shared savings?

Accepted Answer

Two risk options remain: Global (100% of savings and losses, with capitation and specialty episode options) and Professional (up to 60% of savings under the July 2026 methodology paper, up from 50% in the RFA, and 50% of losses; a four-year minimum before moving to Global). The Global discount is lower than REACH's PY2026 4.0% (updated Oct 2026): a flat 3.0% for lower-spending ACOs and 1.75% in 2027 rising to 3.0% by 2032 for higher-spending ACOs; Professional carries no discount. All ACOs have a 3% quality withhold earned back on performance and a 2% retention reduction if they leave after PY1. There is no minimum savings or loss rate, so savings and losses are first-dollar. Risk corridors widen to plus or minus 15% of benchmark in the first band for Global. Higher-spending ACOs receive a 1.5% administrative add-on paid upfront as non-reconciled capitation. Optional residual-based stop-loss reinsurance continues as in REACH PY2026, with a prospectively set attachment point and a per-beneficiary charge (updated Oct 2026). We model your PY2027 result under Global and Professional using your own base-year data, then set the operating targets that determine whether first-dollar risk works in your favor: avoidable admissions, post-acute utilization, and the readmission and unplanned admission measures tied to the 3% withhold. Because losses start at dollar one, we prioritize the practices and service lines with the largest swing and put transformation resources there first.

Question 11

What does 'no rebasing for ten years' really mean for our benchmark, and how is it trended?

Accepted Answer

The LEAD benchmark is built once from a fixed three-year baseline (CY2024 to CY2026 for PY2027; renewing ACOs weight the years roughly equally, newly entering ACOs 10/30/60) and is never rebased through 2036, so the savings you generate are not ratcheted out of future targets. The trend is a three-way blend: two-thirds a national and regional blend (national weight rises with your market share) and one-third an administratively set prospective trend, with guardrails that keep the blended trend within +0.3/−0.2 percentage points of actual national-regional growth in PY2027, widening to +1.5/−1.0 points from PY2031 (updated Oct 2026). ACO-specific adjustments are capped at 5% of the risk-standardized national spend (3% for lower-spending ACOs with more than 40% of participant TINs in an MSSP ACO in the prior two years) (updated Oct 2026): a regional efficiency adjustment worth 50% of the regional-to-historical difference for lower-spending Global ACOs, and a prior savings adjustment worth 50% of your prior three-year average savings. A regional rate book is phased in only after the first five years of the model (updated Oct 2026). Milliman estimates LEAD benchmarks run about 2.3% below MSSP in aggregate and 2.9% lower for regionally efficient ACOs, which is why some low-cost ACOs are staying in MSSP. Nelangie Cares helps you decide whether the fixed benchmark is an asset or a trap for your specific spend profile, and then builds the practice-level engine to beat it year after year. Our monthly reporting tracks per-beneficiary spend by practice against the benchmark trend so drift is caught in the quarter it happens. For ACOs whose base years include practices with poor documentation, we run a base-year data validation so the benchmark you lock in for a decade reflects reality.

Question 12

How does LEAD handle risk adjustment and coding, and how does that interact with what is happening in MA?

Accepted Answer

LEAD uses a CMMI prospective model derived from CMS-HCC V28 for aged and disabled beneficiaries and a concurrent model for High Needs beneficiaries. Risk score growth is capped symmetrically at 3% (4% for High Needs, at least through 2028), so aggressive coding cannot raise your benchmark and under-documentation cannot sink it beyond the cap either way. CMS also announced an AI-inferred risk adjustment approach that runs in shadow mode in 2028, blends in at one-third in 2029 and two-thirds in 2030, and is fully in place from 2031. This mirrors the MA direction: encounter-linked diagnoses only, chart review stripped out, and RADV on every contract. Practices that serve both LEAD-aligned and MA members now face the same standard from both programs. We build one documentation standard that satisfies LEAD, MSSP, and MA at once: prospective suspect-condition lists, V28-aligned templates, MEAT documentation, and a coding integrity audit each quarter. The cap makes accuracy, not volume, the goal, so we focus on making sure every legitimately present condition is assessed and documented at a real visit, which also protects your MA contracts against RADV recoupment.

Question 13

Which LEAD capitation and payment options should we choose, and are we ready for them?

Accepted Answer

Primary Care Capitation is required in Professional and optional in Global; the enhanced version pays the greater of 7% of total cost of care minus the base capitation, or 2% of total cost of care. Total Care Capitation (Global only) replaces 100% of fee-for-service for participant providers. A new Non-Primary Care Capitation is not reconciled, and an Advanced Payment Option is. Fee reductions phase in from 1% to 100% between 2027 and 2031 for ACOs that were not in REACH. Financial guarantees range from 2% to 4% of prior-year Parts A and B spend depending on the option. Capitation changes practice cash flow, staffing incentives, and how you pay participants, and most independent practices have never operated under it. We prepare practices for capitation before the first payment lands: modeling each practice's fee-for-service revenue against its capitation share, redesigning schedules and staffing so visits are driven by patient need rather than by billable encounters, and standing up the care management and outreach work that capitation is meant to fund. For the ACO, we help design the internal distribution model so participants see the connection between their workflows and their payment.

Question 14

What are CMS-Administered Risk Arrangements (CARA), and should we use them for specialist integration?

Accepted Answer

CARA is LEAD's specialty episode option for Global ACOs. CMS builds episode-based cost measures for inpatient medical, procedural, chronic, and other episodes (a default track) or lets ACOs design custom arrangements (Max Flex), and it includes a new RISE to Age in Place falls-prevention episode with up to $2,500 in home interventions over three to six months. Target-price reports arrive in Q2 2027, the first CARA performance year is 2028, and the first reconciliation is mid-2029. It arrives alongside the mandatory Ambulatory Specialty Model for heart failure and low back pain starting January 2027 and the TEAM hospital episode model, so specialists in your market will be under episode accountability whether or not you use CARA. We use 2027 to prepare: mapping your referral patterns, identifying the cardiology, orthopedic, and post-acute partners who drive episode cost, and building the primary care side of the episode (pre-referral optimization, transitional care, and follow-up) so you can enter CARA in 2028 with the data and relationships to succeed. Our falls-prevention workflow in primary care doubles as groundwork for the RISE episode.

Question 15

How does beneficiary alignment work in LEAD, and how do we keep and grow aligned lives?

Accepted Answer

Alignment is prospective and claims-based on plurality of primary care qualified evaluation and management services, in two stages (primary care specialties first, then selected chronic-condition specialists), with all FQHC and RHC services counting as primary care. Voluntary alignment through Medicare.gov or a signed form takes precedence and is now at the TIN level. A Hybrid option adds monthly voluntary alignment updates and a one-time mid-year TIN addition on April 1, 2027. Minimums are 5,000 aligned beneficiaries for standard ACOs (3,000 claims-based in a base year), 1,000 growing to 5,000 by PY5 for newly entering ACOs, and 800 growing to 1,600 for High Needs ACOs, with a buffer if you are within 10% of the minimum. Participation is whole-TIN, so every provider in a participant TIN is in. We build the alignment engine at the practice level: a pending-appointment and unseen-patient report so every eligible beneficiary has a qualifying primary care visit inside the lookback window, a voluntary alignment workflow at check-in, and a monthly roster reconciliation against CMS alignment reports. For ACOs near a minimum, we prioritize the practices with the largest unaligned Medicare panels and coach them on visit cadence.

Question 16

What is the High Needs designation, and is the Medicaid integration pilot relevant to us?

Accepted Answer

LEAD drops REACH's separate High Needs ACO type and makes High Needs a universal beneficiary category with its own benchmark, concurrent risk adjustment, and a 4% symmetric risk score cap. Beneficiaries qualify through a mobility-impairing condition, frailty markers, a risk score of 3.0 or higher, a score between 2.0 and 3.0 with two or more unplanned admissions, or 45 or more SNF days in a year; designation is retroactive quarterly and permanent once met. ACOs where 40% or more of the population is High Needs can use lower alignment minimums but must offer 24/7 access, advance care planning, and home-based care. The Medicaid integration pilot is in a planning phase from March 2026 through December 2027; CMS will pick two states with large dual populations, and states or their managed care plans would contract directly with ACOs. No states have been named. Nelangie Cares builds the High Needs care model inside your practices: identification from claims and EHR data, nurse-led care management with home and telehealth touches, advance care planning workflows, and transitional care after every admission. For ACOs with large dual-eligible panels, we prepare the multilingual outreach and social-needs workflows that a Medicaid contract would require, so you are ready if your state is selected.

Question 17

Which benefit enhancements and beneficiary incentives should we turn on in 2027?

Accepted Answer

LEAD retains the REACH toolkit: the 3-day SNF rule waiver, telehealth flexibilities including asynchronous dermatology and ophthalmology, post-discharge and care management home visits, the home health homebound waiver, concurrent hospice care, and expanded nurse practitioner and physician assistant authority. New for 2027 in Global is medical nutrition therapy for prediabetes and hyperlipidemia. Beneficiary incentives include Part B cost-sharing support, a chronic disease prevention reward (healthy food up to $150), and in-kind items. Every ACO must adopt a Prevention and Quality Plan on a cardiovascular, falls, or nutrition track, and that plan earns up to 5 quality points in the first two years and up to 10 afterward. CMS is also considering a Part D premium buydown by 2029. We help you select the enhancements that match your population and then operationalize them in the practices, which is where most REACH ACOs fell short: SNF waiver protocols for hospitalists and case managers, post-discharge home visit scheduling inside the TCM workflow, and a Prevention and Quality Plan that is built into rooming steps rather than filed with CMS and forgotten. Our blood pressure and falls programs map directly to the cardiovascular and falls tracks.

Question 18

How is quality scored in LEAD, and what do our practices have to do differently?

Accepted Answer

LEAD keeps five REACH measures: risk-standardized all-condition readmissions, unplanned admissions for patients with multiple chronic conditions, days at home for patients with complex chronic conditions, timely follow-up after acute exacerbations, and CAHPS. It adds two MSSP eCQMs, Controlling High Blood Pressure and Diabetes glycemic status above 9%, which are optional in 2027 and 2028, pay-for-reporting in 2029 and 2030, and pay-for-performance from 2031. The score determines how much of the 3% withhold you earn back; unearned withhold funds a high-performer pool. The health equity benchmark adjustment and health equity plan from REACH do not appear in LEAD. We build the two eCQMs into your practices now, while they are optional, so structured blood pressure and A1c data are flowing and validated long before 2031. For the claims-based measures we run the workflows that move them: transitional care within 48 hours of discharge, a follow-up visit within 7 to 14 days of an exacerbation, and chronic care management for the multi-condition population. Our monthly reports show each practice's contribution to the ACO's readmission and unplanned admission rates.

Question 19

We are staying in MSSP. How does the CY 2027 PFS proposed rule change our economics and reporting?

Accepted Answer

Several proposals move money. BASIC Level E sharing rises from 50% to 60% (matching LEAD Professional). One-sided risk in BASIC is capped at five years for agreements starting in 2027. The ENHANCED regional adjustment weight for lower-spending ACOs drops from 50% to 35%, the prior-savings scaling factor rises from 50% to 75%, and the 5% cap on upward adjustments becomes risk-adjusted. The prospective trend is reformed to an annual basis with guardrails, applied retroactively to 2024 to 2026 starters. Prepaid shared savings ends after the 2027 cohort, advance investment payments become a flat $45 or $25 per beneficiary from 2028, and Part B cost-sharing support is allowed from April 2027. APP Plus shrinks to eight measures, MIPS CQMs are extended with the reporting incentive, Medicare CQMs move to flat benchmarks, and CEHRT can be met through three pathways. For 2028, primary care billed under non-ACO TINs is excluded from assignment. CMS scores the package at $5.5 billion in savings over ten years. We translate the rule into a reconciliation forecast for your ACO and each participant TIN, then deploy the transformation framework in the practices that are consuming rather than creating savings. On reporting, we run an eCQM readiness audit across participant EHRs, fix structured data capture at the source, and stand up a practice-level APP Plus dashboard tracked against the 40th-percentile threshold. We also map your TIN structure against the 2028 assignment rules so no practice loses attributed lives by accident.

Question 20

We also hold MA percent-of-premium and shared savings contracts. How do the 2027 MA changes hit those?

Accepted Answer

Plan premium is the base of every percent-of-premium deal, and 2027 premiums are being pulled down by the exclusion of unlinked chart review diagnoses, the frozen V28 model, and plan bids built for margin. Plans are responding by shifting RADV recoupment risk into provider contracts, adding quality gates tied to Star measures that now carry more weight (blood pressure, diabetes, kidney evaluation, screenings, risk-adjusted adherence, functional status, and the 3x-weighted physical and mental health survey measures), and narrowing supplemental benefits. Your ACO's MA revenue in 2027 depends on prospective, encounter-based documentation in your own practices, because the plan can no longer backfill it. We run one HCC governance and Star measure program across the network that serves your Medicare ACO contract and your MA contracts at the same time: coding integrity audits, suspect-condition workflows, practice-level gap reports, a pharmacy adherence workflow coordinated with plan pharmacy teams, and functional status, fall risk, and depression screening as standard rooming steps. We also review your MA contracts for clawback, withhold, and data-sharing terms and give you a negotiation position grounded in documented performance.

Question 21

How do we get dozens of independent practices to actually change how they work, whether we are in LEAD or MSSP?

Accepted Answer

Most ACO performance problems are practice workflow problems: the right patients are not scheduled, the right data is not captured, and the right follow-up does not happen. A 10-year benchmark, first-dollar risk, capitation, and eCQM reporting all raise the cost of that gap. Dashboards alone do not fix it, and neither do compliance memos. The practices that improve are the ones where someone with clinical and operational credibility sits with the team, looks at their own data, and rebuilds the workflow with them. That is the Nelangie Cares model. Our Data-Driven Care Delivery Transformation Framework moves each practice through six stages: diagnose through data, build alignment through structured conversations, assess workflows, redesign with the practice, pilot and shadow the new workflow, and monitor reliability before looping back to the data. We work inside the practice's EHR, redesign templates, train staff, and stay through the pilot. ACOs engage us as fractional regional quality leadership or for defined practice transformation sprints, and the same engagement serves LEAD, MSSP, and MA requirements at once.

Question 22

What is the real net revenue picture for 2027 after all the moving parts?

Accepted Answer

The 2.48% average increase (4.98% with coding trend) is the gross figure. Against it: unlinked chart review diagnoses are excluded (-1.53%), normalization and the frozen V28 model take -1.12%, rebasing takes -0.17%, and the coding pattern adjustment stays at 5.90%. On the Part D side, the premium stabilization demonstration ends after 2026, the national average bid is $296.05, and the 2027 deductible and out-of-pocket cap rise to $700 and $2,400. Your Star Rating determines whether you keep 65% or 70% of the bid-benchmark difference as rebates, and CMS expects the Star changes to shift bonus dollars, with about a quarter of contracts projected to lose half a star. Nelangie Cares helps you protect the two levers you still control: the accuracy of encounter-based risk documentation in your network and the clinical Star measures your providers drive. We work as your provider-enablement partner, going into contracted primary care practices to rebuild documentation, care management, and gap-closure workflows, so the revenue you lost from retrospective chart review is replaced by compliant, prospective capture.

Question 23

We are losing unlinked chart review revenue. How do we replace it compliantly?

Accepted Answer

Only diagnoses tied to an encounter count from 2027, with an exception for members who switch MA organizations. In-home health risk assessments still count, but MedPAC has formally asked CMS to exclude them and to look at linked chart reviews next, so building a strategy on HRAs is building on sand. The durable answer is that your contracted providers assess and document conditions at real visits, which requires them to have the tools, the suspect lists, and the visit cadence to do it. We design and run a provider enablement program on your behalf: pre-visit suspect-condition reports fed to practices, EHR template redesign for V28 documentation, two-day staff training on MEAT documentation, and a monthly recapture scorecard by practice. Because we are clinicians working inside practices, adoption is far higher than with vendor portals, and the documentation holds up under RADV review because it was created at the point of care.

Question 24

Every contract now gets a RADV audit with up to 200 records. How do we lower our exposure?

Accepted Answer

CMS expanded its coder workforce to about 2,000, audits all contracts annually, and is issuing record requests for payment years 2020 through 2025 on a rolling schedule into 2027. Extrapolation is currently vacated after Humana v. Becerra, but the Fifth Circuit appeal is pending and a reversal would apply retroactively to the years being audited now. Your exposure is the share of submitted HCCs that lack adequate support in the provider's record, and that share is determined in the exam room, not in your coding department. We run network documentation audits that mimic RADV: sample submitted HCCs, retrieve the record, and score support. We report unsupported-diagnosis rates by practice and by condition, then fix the highest-risk practices with template changes, education, and a record-retrieval process that gets records back to you in days. This also gives you the data to remove unsupported diagnoses before submission rather than after an audit.

Question 25

What should we focus on for the 2027 and 2028 Star Ratings?

Accepted Answer

With eleven administrative measures leaving, each remaining measure carries more weight. The clinical measures and the three adherence measures stay at high weight, Improving or Maintaining Physical and Mental Health are 3x for the 2027 ratings, four new 1x measures have no cut-point guardrail in their first year, and adherence measures become risk-adjusted for MY2026 (treated as new, 1x, in the 2028 ratings, returning to 3x in 2029). Cut points remain subject to Tukey outlier deletion, so the bar keeps rising as low performers are removed. The 4-star line is worth 5% of benchmark plus a higher rebate share. We build the provider-side program for the measures plans cannot close from a call center: blood pressure and diabetes control, kidney evaluation, screenings, functional status and depression screening at every visit, deprescribing for polypharmacy and opioid-benzodiazepine overlap, and adherence outreach coordinated with your pharmacy team. We report practice-level performance monthly so your Star team can target incentives where they will change the rating.

Question 26

We are cutting benefits and expect churn. How do we retain members and hold the medical loss ratio?

Accepted Answer

Members are more likely to switch when benefits shrink, and the CY 2027 rule requires objective, published eligibility criteria for Special Supplemental Benefits for the Chronically Ill and real-time verification on benefit debit cards, which narrows the levers you used to differentiate. Meanwhile, MLR pressure comes from avoidable emergency visits and admissions in the moderate-risk population that is least engaged with primary care. We help you turn primary care into the retention benefit: practices in your network that run Chronic Care Management, Transitional Care Management, and high-utilizer monitoring keep members engaged and out of the hospital. We stand up those programs in contracted practices, with condition-specific care plans and multilingual support, and we report the utilization impact so you can show the value to your actuaries and to members.

Question 27

How should we restructure provider value-based contracts for 2027?

Accepted Answer

Percent-of-premium deals now sit on a smaller premium, and simply passing RADV recoupment and the chart review loss down to providers will drive your best primary care groups to competitors or to ACOs. The plans that will win 2027 are the ones that pay for the behaviors the rules now reward: encounter-based documentation, Star measure closure, care management, and low avoidable utilization, and that invest in provider capability rather than only in incentives. Nelangie Cares can be the practice transformation partner you fund for your network, a neutral clinical team that helps providers meet the terms of the contract. We help you design quality-weighted capitation and shared savings tied to the specific Star and utilization measures that move your rating and MLR, and we deliver the practice-level implementation so the contract produces results instead of disputes.

Question 28

What do we owe under the CMS-0057 prior authorization rule, and how do we get providers to use it?

Accepted Answer

By Jan 1, 2027, MA plans must operate a FHIR-based prior authorization API, decide urgent requests within 72 hours and standard requests within 7 days, give specific denial reasons, and publicly report prior authorization metrics. The CY 2027 rule added no further utilization management restrictions, but the CY 2024 rules on coverage criteria and continuity remain in force. Provider adoption of the API is the weak link; most practices still fax. We work with your contracted practices to redesign their authorization intake so requests are submitted electronically and complete, and we track denial and turnaround patterns by practice and service. The result is lower administrative cost on both sides, fewer complaints, and better performance on the access and experience measures that still count.

Question 29

How do the Part D changes and dual-eligible rules affect our D-SNP and adherence strategy?

Accepted Answer

The 2027 Part D benefit has a $700 deductible and a $2,400 out-of-pocket cap, a new RxHCC model with separate MA-PD and PDP segments, and the end of the premium stabilization demonstration. Adherence measures become risk-adjusted for MY2026 and remain the highest-weighted Part D measures. For D-SNPs, CMS kept the current supplemental benefit pathway and removed some integration sanctions, but the frailty factors were recalibrated and dual populations remain the hardest to keep adherent. Our CCM programs include medication reconciliation, adherence coaching, and refill coordination as standard components, delivered in the member's language through nurse-led outreach with AI-supported interpretation. We work with your pharmacy and MTM teams so the same members are not contacted three times and so adherence gaps are closed by the clinician the member already trusts.

CY 2027 Medicare Advantage & Value-Based Care FAQ

CY 2027 at a glance

Primary Care Providers

ACO Executives

Payors

How Nelangie Cares closes the gaps

Value-Based Care Readiness & Revenue Exposure Review

EHR Root-Cause Analysis & Workflow Redesign

Quality Gap & Population Reporting

Risk Adjustment Documentation Integrity & RADV Readiness

Care Management Program Build (CCM, TCM, AWV, APCM, ACP)

ACO & Payor Contract Navigation

Fractional Regional Quality Leadership

Notes and sources